Clinical Trials
4
Active:2
Completed:2
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- GamaMabs Pharma
- Target Recruit Count
- 65
- Registration Number
- NCT03799731
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪UZ Gasthuisberg, Gent, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- GamaMabs Pharma
- Target Recruit Count
- 78
- Registration Number
- NCT02978755
- Locations
- 🇧🇪
Institut Bordet, Brussels, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇫🇷CHU Besançon, Besançon, France
News
No news found